Targeting the S and G2 checkpoint to treat cancer

Drug Discovery Today

Volumn 17, Issue 5-6, 2012, Pages 194-202

  Chen, Tao ^a   Stephens, Peter A ^a   Middleton, Fiona K ^a   Curtin, Nicola J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; ARRY 575; ATR PROTEIN; AZD 7762; BIOLOGICAL MARKER; CEP 3891; CHECKPOINT KINASE 1; CISPLATIN; CYTARABINE; CYTOSINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GDC 0245; GEMCITABINE; HISTONE H2AX; HYDROXYUREA; IRINOTECAN; LY 2606368; PD 321852; PF 00477736; PROTEIN SERINE THREONINE KINASE INHIBITOR; SAR 020106; SCH 900776; TOPOTECAN; UNCLASSIFIED DRUG; V 158411; VELIPARIB; XL 9844;

ADVANCED CANCER; CANCER CELL; CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIZATION; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; ENZYME PHOSPHORYLATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE INACTIVATION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPOTENSION; IN VITRO STUDY; LEUKEMIA; LYMPHOMA; NEUTROPENIA; OVARY CANCER; PROTEIN FUNCTION; RADIOSENSITIZATION; REVIEW; S PHASE CELL CYCLE CHECKPOINT; SEPSIS; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG EVALUATION, PRECLINICAL; G2 PHASE; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; S PHASE;

EID: 84863232671     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.12.009     Document Type: Review

References (90)

1. M.M. Vilenchik, and A. Knudson Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer Proc. Natl Acad. Sci. U. S. A. 100 2003 12871 12876
2. A. Poehlmann, and A. Roessner Importance of DNA damage checkpoints in the pathogenesis of human cancers Pathol. Res. Pract. 206 2010 591 601
3. Y. Shiloh The ATM-mediated DNA-damage response: taking shape Trends Biochem. Sci. 31 2006 402 410
4. J. Smith The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer Adv. Cancer Res. 108 2010 73 112
5. C.J. Sherr Cancer cell cycles Science 274 1996 1672 1674
6. J. Massague G1 cell-cycle control and cancer Nature 432 2004 298 306
7. M.D. Garrett, and I. Collins Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharm. Sci. 32 2011 308 316
8. E.J. Brown, and D. Baltimore ATR disruption leads to chromosomal fragmentation and early embryonic lethality Genes Dev. 14 2000 397 402
9. H. Takai Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice Genes Dev. 14 2000 1439 1447
10. Q. Liu Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint Genes Dev. 14 2000 1448 1459
11. G. Zachos Lethal errors in checkpoint control - life without Chk1 Cell Cycle 2 2003 14 16
12. M. O'Driscoll A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome Nat. Genet. 33 2003 497 501
13. H. Takemura Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks J. Biol. Chem. 281 2006 30814 30823
14. R.L. Flynn, and L. Zou ATR: A master conductor of cellular responses to DNA replication stress Trends Biochem. Sci. 36 2011 133 140
15. J. Zhang Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin Mol. Cancer Res. 7 2009 1510 1516
16. I. Mamely Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery Curr. Biol. 16 2006 1950 1955
17. M. Walker Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity Oncogene 28 2009 2314 2323
18. D. Wilsker Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control Proc. Natl Acad. Sci. U. S. A. 105 2008 20752 20757
19. Y. Dai, and S. Grant New insights into checkpoint kinase 1 in the DNA damage response signaling network Clin. Cancer Res. 16 2010 376 383
20. G.I. Shapiro, and J.W. Harper Anticancer drug targets: cell cycle and checkpoint control J. Clin. Invest. 104 1999 1645 1653
21. A. Duensing A role of the mitotic spindle checkpoint in the cellular response to DNA replication stress J. Cell Biochem. 99 2006 759 769
22. W.A. Cliby Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints EMBO J. 17 1998 159 169
23. P. Nghiem ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation Proc. Natl Acad. Sci. U. S. A. 98 2001 9092 9097
24. L. Carrassa Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53 Cell Cycle 3 2004 1177 1181
25. K. Flatten The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons J. Biol. Chem. 280 2005 14349 14355
26. M. Ganzinelli Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil Clin. Cancer Res. 14 2008 5131 5141
27. Y. Pan Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis Cancer Biol. Ther. 8 2009 1559 1566
28. N. Sangster-Guity ATR mediates cisplatin resistance in a p53 genotype-specific manner Oncogene 30 2011 2526 2533
29. W.J. Kim Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line Oncogene 21 2002 3864 3871
30. L.M. Karnitz Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival Mol. Pharmacol. 68 2005 1636 1644
31. S. Zenvirt Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents Oncogene 29 2010 6149 6159
32. S.H. Cho Chk1 is essential for tumor cell viability following activation of the replication checkpoint Cell Cycle 4 2005 131 139
33. C.X. Ma Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics Trends Mol. Med. 17 2011 88 96
34. S. Ashwell, and S. Zabludoff DNA damage detection and repair pathways - recent advances with inhibitors of checkpoint kinases in cancer therapy Clin. Cancer Res. 14 2008 4032 4037
35. J.M. Wagner, and S.H. Kaufmann Prospects for the use of ATR inhibitors to treat cancer Pharmaceuticals 3 2010 1311 1334
36. C. Courage Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation Br. J. Cancer 71 1995 697 704
37. C.S. Sorensen Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A Cancer Cell 3 2003 247 258
38. Y. Luo Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism Neoplasia 3 2001 411 419
39. P.C. Mack Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma Cancer Chemother. Pharmacol. 51 2003 337 348
40. T. Furuta p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine Oncogene 25 2006 2839 2849
41. L.A. Parsels Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells Mol. Cancer Ther. 8 2009 45 54
42. A. Blasina Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 Mol. Cancer Ther. 7 2008 2394 2404
43. S.D. Zabludoff AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies Mol. Cancer Ther. 7 2008 2955 2966
44. T.J. Guzi Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening Mol. Cancer Ther. 10 2011 591 602
45. M.I. Walton The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106 Mol. Cancer Ther. 9 2010 89 100
46. D.J. Matthews Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo Cell Cycle 6 2007 104 110
47. S. McNeely Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase Cell Cycle 9 2010 995 1004
48. P.T. Ferrao Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells Oncogene 2011 10.1038/onc.2011.358
49. A. Hoglund Therapeutic implications for the induced levels of chk1 in myc-expressing cancer cells Clin. Cancer Res. 17 2011 7067 7079
50. C. Mitchell Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells Mol. Pharmacol. 78 2010 909 917
51. C. Zhang PF-0077736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts Clin. Cancer Res. 15 2009 4460 4630
52. C.E. Redon Histone {gamma}H2AX and Poly(ADP-Ribose) as clinical pharmacodynamic biomarkers Clin. Cancer Res. 16 2010 4532 4542
53. J.S. Dickey H2AX: functional roles and potential applications Chromosoma 118 2009 683 692
54. J.B. Mitchell In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762 Clin. Cancer Res. 16 2010 2076 2084
55. R.G. Syljuasen Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing radiation Cancer Res. 64 2004 9035 9040
56. H. Yang Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy Biochem. Biophys. Res. Commun. 406 2011 53 58
57. L. Petersen p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors Cell Prolif. 43 2010 365 371
58. E.A. Sausville Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms J. Clin. Oncol. 19 2001 2319 2333
59. E.C. Dees A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors Clin. Cancer Res. 11 2005 664 671
60. R.P. Perez Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850) Clin. Cancer Res. 12 2006 7079 7085
61. S.J. Hotte Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study Ann. Oncol. 17 2006 334 340
62. P.M. Fracasso A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies Cancer Chemoth. Pharm. 67 2011 1225 1237
63. N. Brega Phase 1 clinical trial of gemcitablne (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase ASCO Annual Meeting Chicago 2010
64. A. Daud A Phase I dose-escalation study of SCH-900776, a selective inhibitor of checkpoint 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumours ASCO Annual Meeting Chicago 2010
65. E. Sausville Phase 1 dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumours ASCO Annual Meeting 2011
66. A.L. Ho Phase 1, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumours ASCO Annual Meeting 2011
67. D. Cortez Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases J. Biol. Chem. 278 2003 37139 37145
68. J.N. Sarkaria Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine Cancer Res. 59 1999 4375 4382
69. Z.A. Knight A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling Cell 125 2006 733 747
70. H. Nishida Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response Nucleic Acids Res. 37 2009 5678 5689
71. F. Essmann Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event Cancer Res. 64 2004 7065 7072
72. J.D. Charrier Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents J. Med. Chem. 54 2011 2320 2330
73. P.M. Reaper Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR Nat. Chem. Biol. 7 2011 428 430
74. A. Peasland Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines Br. J. Cancer 105 2011 372 381
75. L.I. Toledo A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations Nat. Struct. Mol. Biol. 18 2011 721 727
76. E.A. Nam T1989 phosphorylation is a marker of active ataxia telangiectasia-mutated and rad3-related (ATR) kinase J. Biol. Chem. 286 2011 28707 28714
77. S. Liu ATR autophosphorylation as a molecular switch for checkpoint activation Mol. Cell 43 2011 192 202
78. D. Rossetto Epigenetic modifications in double-strand break DNA damage signaling and repair Clin. Cancer Res. 16 2010 4543 4552
79. L.A. Parsels Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition Clin. Cancer Res. 17 2011 3706 3715
80. M.A. Morgan Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair Cancer Res. 70 2010 4972 4981
81. V. Leung-Pineda Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit Mol. Cell Biol. 26 2006 7529 7538
82. J.M. Wagner, and L.M. Karnitz Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival Mol. Pharmacol. 76 2009 208 214
83. C.C. Chen CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors Mol. Cancer 8 2009 24
84. S. Neijenhuis Targeted radiosensitization of cells expressing truncated DNA polymerase {beta} Cancer Res. 70 2010 8706 8714
85. C. Kiyohara Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis Lung cancer 54 2006 267 283
86. D. Starcevic Is there a link between DNA polymerase beta and cancer? Cell Cycle 3 2004 998 1001
87. C.V. Dang Function of the c-Myc oncogenic transcription factor Exp. Cell Res. 253 1999 63 77
88. G.S. Orphanos Cardiotoxicity induced by tyrosine kinase inhibitors Acta Oncol. 48 2009 964 970
89. Y. Dai Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism Blood 100 2002 3333 3343
90. P.N. Lara The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial Clin. Cancer Res. 11 2005 4444 4450